Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Moderna stock crumbled Thursday after the biotech company missed sales estimates for its two products, Spikevax and mResvia.

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The ...

Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

The US Department of Health and Human Services said it will require that all new vaccines be tested in placebo-controlled trials before they’re licensed for use, raising urgent ...

HHS announced that the government will invest $176 million in Moderna to expedite the creation of a pandemic influenza vaccine.

We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a ...

Pharmaceutical company Moderna ( NASDAQ: MRNA) is set to report its first quarter earnings results on Thursday, May 1st, ...